Loading...
XKRX
214390
Market cap98mUSD
Dec 05, Last price  
6,080.00KRW
1D
0.16%
1Q
23.20%
Jan 2017
-56.42%
IPO
-81.00%
Name

Kyongbo Pharmaceutical Co Ltd

Chart & Performance

D1W1MN
XKRX:214390 chart
P/E
31.33
P/S
0.61
EPS
194.06
Div Yield, %
Shrs. gr., 5y
Rev. gr., 5y
4.47%
Revenues
238.56b
+10.26%
169,781,246,180178,032,632,080186,726,169,860191,661,374,450201,343,595,540191,706,189,110215,285,095,140170,659,645,040196,264,902,080216,357,481,790238,556,126,000
Net income
4.64b
+55.98%
8,635,953,72026,109,623,15012,705,929,80017,963,309,61013,116,049,3905,285,239,3909,404,446,290-7,495,178,990610,590,0902,974,400,4604,639,326,000
CFO
149m
-96.92%
16,041,866,8704,240,141,97025,328,802,77025,805,145,560-1,138,159,26023,668,110,96020,795,227,48017,967,902,72010,126,730,8404,844,320,330149,116,000
Dividend
Dec 27, 202350 KRW/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Kyongbo Pharmaceutical Co., Ltd manufactures and sells active pharmaceutical ingredients in South Korea. The company offers general, cephalosporins, and anti-cancer APIs; prescription drugs, including anesthetic, cardiovascular, digestive, and antibiotics; and OTC drugs. It also exports its products to 30 countries worldwide. The company was formerly known as Kyongbo Chemical Co. Ltd. and changed its name to Kyongbo Pharmaceutical Co., Ltd in March 2002. Kyongbo Pharmaceutical Co., Ltd was founded in 1987 and is headquartered in Asan, South Korea.
IPO date
Jun 29, 2015
Employees
Domiciled in
KR
Incorporated in
KR

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT